Phase 4 N=150 Study Comparing Treatment With Alluzience vs Reconstituted Toxin
Glabellar Frown Lines
Primary: Time Needed to Prepare Alluzience and Powder BoNT A — 0.55; 1.57 Minutes
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=111 Precedex Special Investigation (in Pediatric Patients)
Sedation
Primary: Number of Participants With Adverse Drug Reactions — 9; 2 Participants
N/A N=23 Optimization of Transcutaneous Electrical Acustimulation (TEA) Modalities for Treatment of IBS-C
IBS · Constipation
Primary: Change in Pressure of Maximum Tolerance in mmHg of the Rectum as Measured by a Barostat Device When Compared to Pre-TEA Administration. — 0.79; 1.32; -4.44; -4.21 mmHg…
Phase 3 N=43 A Clinical Study to Evaluate the Maximum Maxillary Bite Force (BF) When Using Two Novel Denture Adhesives Compared to Using No-Adhesive
Denture Retention
Primary: Area Over Baseline Over 12 Hours (AOB 0-12) to Compare Maximum Incisal Bite Force — 0.87; 0.69; 0.89; 0.59 lbs — p=0.037
Phase 2 N=38 Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19
Confirmed Coronavirus Disease
Primary: Number of Participants With Each Score on WHO 7-point Outcome Scale at Day 7 — 6; 0; 20; 8 Participants — p=0.0346
N/A N=14 Vascular Dysfunction During Physical Inactivity
Aging · Vascular Endothelium · Skeletal Muscle
Primary: Brachial Artery Vascular Function — 5.1; 3.1; 4.4 percent vasodilation
Phase 2 N=53 Autologous Cell Therapy for Treatment of Fecal Incontinence
Fecal Incontinence
Primary: Number of Treatment-Related Adverse Events — 0; 1; 5; 28 events
N/A N=47 Cemented Versus Cementless Unicompartmental Knee Arthroplasty
Osteoarthritis, Knee
Primary: Radiostereometric Analysis Examination - Translations — -0.01; 0.05; -0.10; -0.17 millimetres
Phase 1 N=23 A STUDY TO COMPARE THE PHARMACOKINETICS OF PF-06835919 IN PARTICIPANTS WITH AND WITHOUT HEPATIC IMPAIRMENT
Hepatic Impairment · Healthy Participants
Primary: Area Under the Plasma Concentration-time Curve From Time 0 Extrapolated to Infinite Time (AUCinf) of PF-06835919 — 14090; 13090; 18930; 19630 nanogram*hour per…
Phase 3 N=1,177 Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)
Non-small Cell Lung Cancer
Primary: Disease-Free Survival (DFS) — 53.8; 43.0 Months
N/A N=67 Novel Executive Function Training for Obesity
Overweight and Obesity
Primary: Feasibility as Measured by Attendance — 18; 18 Sessions
Phase 3 N=22 68Ga PSMA in Preprostatectomy Patients
Prostate Cancer · Prostatic Neoplasm · Prostatic Neoplasms, Castration-Resistant
Primary: Sensitivity of Ga 68-labeled PSMA-11 Positron Emission Tomography/Computed Tomography (PET/CT) for the Detection of Regional Pelvic Nodal Metastases on a Per Patient…
N/A N=668 Optimization of a New Adaptive Intervention to Increase COVID-19 Testing
COVID-19 Testing
Primary: Stage 1: Completion of COVID-19 Test After First Randomization — 78; 71; 0; 0 participants
N/A N=572 Pilot Study of Targeted Normoxia in Critically Ill Trauma Patients
Trauma · Critical Illness · Oxygen Toxicity
Primary: Patient-time Hyperoxic and Not on Room Air — 40.6; 33.9 Percent patient-time in hyperoxia — p=0.03
Phase 2 N=50 Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant
Chronic Myelomonocytic Leukemia · de Novo Myelodysplastic Syndrome · Myelodysplastic Syndrome
Primary: Failure-free Survival (Failure Defined as Death or Relapse) — 6; 10 Participants